Xeljanz woes are likely to be boost to Rinvoq, which is already growing fast – making $450 million in the first nine months of 2020, including $215 million in the third quarter alone.

There is reported to be off-label use of Xeljanz in alopecia, although that is likely to diminish now that an FDA-approved option is available. The new approval could add some additional momentum ...